- Home
- AEON vs QNME Comparison
AEON vs QNME Comparison
Compare AEON & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | QNME |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Integrated Freight & Logistics |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 14.1M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AEON | QNME |
|---|---|---|
| Price | $0.16 | $0.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.82 | N/A |
| AVG Volume (30 Days) | 613.6K | ★ 639.2K |
| Earning Date | 11-24-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $0.13 | $0.26 |
| 52 Week High | $1.45 | $1.40 |
Technical Indicators
Market Signals| Indicator | AEON | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 39.77 |
| Support Level | $0.13 | $0.28 |
| Resistance Level | $0.33 | $0.43 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.78 | 6.34 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About QNME Quanome Technologies Inc. Common Stock
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.